Asia News
Filter News
Found 32,704 articles
-
On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.
-
Research Roundup for Friday, May 24.
-
CTONG-OrigiMed New Clinical Trial Sharing Platform Launched during the 3rd OrigiMed Summit for Cancer Discovery
5/24/2019
With fast advances in the medical industry, on May 11, 2019, the third OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was successfully held in Guangzhou.
-
B dot Medical Developing Ultra-compact Proton Cancer Therapy System That Can Replace X-ray Cancer Therapy System
5/24/2019
B dot Medical Inc. announced on May 24 that the company has initiated the development of an ultra-compact proton cancer therapy system that can replace the commonly used x-ray cancer therapy system.
-
Molecules Swing Electrolytes across Membranes to Kill Cancer Cells
5/23/2019
Researchers from Singapore have designed the world’s first ‘molecular swing’ to transport electrolytes across cell membranes.
-
Self-Destructing Molecules Hold Key to Retard Superbug Development
5/23/2019
Singapore-based researchers have discovered a possible solution to impede the evolution of bacteria into superbugs that are resistant to drugs and therefore harder to kill.
-
Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance
5/23/2019
Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market
-
Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers
5/23/2019
Ascentage Pharma announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
-
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
5/23/2019
The partner of CStone Pharmaceuticals, Agios Pharmaceuticals, Inc. announced that the global Phase 3 ClarIDHy trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation met its primary endpoint.
-
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
5/23/2019
APRINOIA Therapeutics announces that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.
-
MGI introduces total solution for single cell RNA sequencing using MGISEQ-2000 sequencing platform compatible with 10x Genomics
5/23/2019
MGI, a subsidiary of global genomics leader BGI Group, announced it will begin marketing a total solution for single cell RNA Sequencing as part of the 10x Genomics' Compatible Product Partner Program on MGI's MGISEQ and BGISEQ sequencing platform.
-
CPhI China opens with analysis pointing to a surge in growth in 2019
5/23/2019
New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
-
The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
5/23/2019
Can-Fite BioPharma Ltd. announced that it has been selected for a podium presentation in a session of ‘Selected Abstracts of Excellence’ titled, “Namodenoson anti-NAFLD/NASH Activity is Mediated via De-regulation of the Wnt/β-catenin Pathway” at the 2nd Annual International Conference on Fatty Liver in Berlin, Germany which takes place on June 27-29, 2019.
-
Tencent Miying Launches AI-supported Auxiliary Diagnostic System
5/22/2019
Tencent today announces the launch of an AI-supported auxiliary diagnostic system for conducting digital colposcopy at the Global Digital Ecosystem Summit being held in Kunming, China.
-
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
5/22/2019
China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today the launch of a strategic partnership with Future Science & Technology Park of Huangshan Hi-tech Zone and Huangshan Panjie Investment Co., Ltd.
-
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
5/22/2019
The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.
-
Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index
5/22/2019
The Company’s addition to the Morgan Stanley Capital International MSCI Hong Kong Micro Cap Index, effective Tuesday, May 28, 2019, Hong Kong Time.
-
Compugen to Present at the Jefferies 2019 Healthcare Conference
5/22/2019
Compugen Ltd. announced that Anat Cohen-Dayag, PhD, President and CEO, will present a corporate overview and update at the Jefferies 2019 Healthcare Conference in New York, on Tuesday, June 4, 2019, at 4:30 PM ET.
-
Scientists Identify New Therapeutic Target for Fatty Liver Disease
5/22/2019
Enleofen Bio announced the publication of promising data from a preclinical study of a novel therapy targeting a severe form of fatty liver disease.
-
DarioHealth Corp. Announces Pricing of $7.2 Million Public Offering of Common Stock
5/22/2019
DarioHealth Corp. announced the pricing of an underwritten public offering of 4,855,341 shares of common stock at a price to the public of $0.60 per share and pre-funded warrants to purchase 7,175,525 shares of common stock at a price to the public of $0.5999 per pre-funded warrant for aggregate gross proceeds of approximately $7,200,000, before underwriting discounts and offering expenses.